Patent classifications
A61K31/529
METHODS FOR TREATING HAIR LOSS DISORDERS
The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
TREATMENT OF CANCER WITH TG02
The present disclosure provides therapeutic methods of treating a cancer patient with TGO2 and a second therapeutic agent, e.g., TGO2 and an immune checkpoint inhibitor, TGO2 and a COX-2 inhibitor, or TGO2 and an immune checkpoint inhibitor and a COX-2 inhibitor.
TREATMENT OF CANCER WITH TG02
The present disclosure provides therapeutic methods of treating a cancer patient with TGO2 and a second therapeutic agent, e.g., TGO2 and an immune checkpoint inhibitor, TGO2 and a COX-2 inhibitor, or TGO2 and an immune checkpoint inhibitor and a COX-2 inhibitor.
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
- Jason McCartney ,
- Alexander Russell Abela ,
- Sunny Abraham ,
- Corey Don ANDERSON ,
- Vijayalaksmi Arumugam ,
- Jaclyn CHAU ,
- Jeremy CLEMENS ,
- Thomas Cleveland ,
- Timothy Richard Coon ,
- Timothy A. DWIGHT ,
- Lev Tyler Dewey Fanning ,
- Bryan A. Frieman ,
- Peter Grootenhuis ,
- Anton V. Gulevich ,
- Sara Sabina Hadida Ruah ,
- Yoshihiro ISHIHARA ,
- Haripada Khatuya ,
- Paul KRENITSKY ,
- Vito Melillo ,
- Mark Thomas MILLER ,
- Prasuna Paraselli ,
- Fabrice Pierre ,
- Alina SILINA ,
- Joe A. TRAN ,
- Johnny Uy ,
- Lino Valdez ,
- Troy Vickers ,
- Jinglan Zhou
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.
##STR00001##
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
- Jason McCartney ,
- Alexander Russell Abela ,
- Sunny Abraham ,
- Corey Don ANDERSON ,
- Vijayalaksmi Arumugam ,
- Jaclyn CHAU ,
- Jeremy CLEMENS ,
- Thomas Cleveland ,
- Timothy Richard Coon ,
- Timothy A. DWIGHT ,
- Lev Tyler Dewey Fanning ,
- Bryan A. Frieman ,
- Peter Grootenhuis ,
- Anton V. Gulevich ,
- Sara Sabina Hadida Ruah ,
- Yoshihiro ISHIHARA ,
- Haripada Khatuya ,
- Paul KRENITSKY ,
- Vito Melillo ,
- Mark Thomas MILLER ,
- Prasuna Paraselli ,
- Fabrice Pierre ,
- Alina SILINA ,
- Joe A. TRAN ,
- Johnny Uy ,
- Lino Valdez ,
- Troy Vickers ,
- Jinglan Zhou
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.
##STR00001##
Methods and devices for renal nerve blocking
Methods for treating a hypertensive human patient are disclosed herein. A method in accordance with one embodiment comprises delivering a neuromodulatory agent to a renal nerve of the patient via an intravascularly positioned drug delivery catheter. The method includes at least partially blocking neural activity along the renal nerve with the neuromodulatory agent, which results in a therapeutically beneficial reduction in blood pressure of the patient.
Methods and devices for renal nerve blocking
Methods for treating a hypertensive human patient are disclosed herein. A method in accordance with one embodiment comprises delivering a neuromodulatory agent to a renal nerve of the patient via an intravascularly positioned drug delivery catheter. The method includes at least partially blocking neural activity along the renal nerve with the neuromodulatory agent, which results in a therapeutically beneficial reduction in blood pressure of the patient.
USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY
The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY
The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY
The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.